Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Wertheim cung cấp cho các bạn kiến thức về ngành y đề tài: Surgical treatment for pulmonary metastases from esophageal carcinoma after definitive chemoradiotherapy: Experience from a single institution. | Kozu et al. Journal of Cardiothoracic Surgery 2011 6 135 http content 6 1 135 JCTS JOURNAL OF CARDIOTHORACIC SURGERY RESEARCH ARTICLE Open Access Surgical treatment for pulmonary metastases from esophageal carcinoma after definitive chemoradiotherapy Experience from a single institution AA V I lz I 1I 11 r I I c .a z a2 7. r I I I I AZA I I 2 I 11 izz-aCi I ZVA I rV -v. iA3 I I az-aCi I -ZA I Vif II4 -A zl I I A ri 11 I Izz-A Zz A zl Z A 1 YQsniKi Kozu Hiroshi Sato Ydsuniro isuDosa Hirofumi Ogawa Hirofumi Yasui and Haruhiko Kondo Abstract Background Surgical treatment for pulmonary metastases is Known to be a safe and potentially curative procedure for various primary malignancies. However there are few reports regarding the prognostic role of surgical treatment for pulmonary metastases from esophageal carcinoma especially after definitive chemoradiotherapy CRT . Methods We retrospectively reviewed 5 patients who underwent surgical treatment for pulmonary metastases from esophageal carcinoma at our institution. The primary treatment for esophageal carcinoma was definitive CRT and a complete response CR was achieved in all patients. Results The surgical procedure for pulmonary metastases was wedge resection and pathological complete resection was achieved in all 5 patients. The disease free interval after definitive CRT varied from 7 to 36 months with a median of 19 months. There were no perioperative complications but postoperative respiratory failure occurred in 1 patient. The postoperative hospital stay varied from 4 to 7 days with a median of 6 days. Three patients are now alive with a good performance status PS and are disease free. The other 2 patients died of primary disease. The overall survival after surgical treatment varied from 20 to 90 months with a median of 29 months. Conclusions Surgical treatment should be considered for patients with pulmonary metastases from esophageal carcinoma who previously received CRT and .
